The trading price of Puma Biotechnology Inc (NASDAQ:PBYI) closed lower on Friday, November 15, and closing at $2.42, -19.06% lower than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $2.35 and $3.01. The company’s P/E ratio in the trailing 12-month period was 5.10, while its 5Y monthly beta was 1.08. In examining the 52-week price action we see that the stock hit a 52-week high of $7.73 and a 52-week low of $2.22. Over the past month, the stock has lost -14.49% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Puma Biotechnology Inc, whose market valuation is $96.14 million at the time of this writing, is expected to release its quarterly earnings report in December. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by 0.14 per share this quarter, however they have predicted annual earnings per share of 0.5 for current year and 0.6 for next year.
Analysts have forecast the company to bring in revenue of 52.5M for the current quarter, with the likely lows of 51.8M and highs of 53.2M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 223.9M.
On the technical side, indicators suggest PBYI has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned PBYI a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Puma Biotechnology Inc (PBYI) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that PBYI’s price is currently -16.90% off the SMA20 and -11.43% off the SMA50. The RSI metric on the 14-day chart is currently showing 36.09, and weekly volatility stands at 15.36%. When measured over the past 30 days, the indicator reaches 8.85%. Puma Biotechnology Inc (NASDAQ:PBYI)’s beta value is currently sitting at 1.03, while the Average True Range indicator is currently displaying 0.27.
To see how Puma Biotechnology Inc stock has been performing in comparison to its peers in the industry, here are the numbers: PBYI stock’s performance was -19.06% in the latest trading, and -36.32% in the past year. Puma Biotechnology Inc has a P/E ratio of 5.10.
An evaluation of the daily trading volume of Puma Biotechnology Inc (NASDAQ:PBYI) indicates that the 3-month average is 352.06K. However, this figure has increased over the past 10 days to an average of 0.82.
Currently, records show that 47.65 million of the company’s shares remain outstanding. The insiders hold 28.31% of outstanding shares, whereas institutions hold 54.30%. The stats also highlight that short interest as of 2024-10-31, stood at 3.19 million shares, resulting in a short ratio of 14.34 at that time. From this, we can conclude that short interest is 766.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were down slightly from the previous month’s figure, which was 3.41 million. However, since the stock’s price has seen -44.11% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
